Author: Rafael Santos

AIBILI is proud to perform a study on the effectiveness of educational materials available for Vabysmo®, Eylea® and Lucentis®.

The MARVEL Study, supported by INFARMED, I.P., is conducted by the Coimbra Regional Pharmacovigilance Unit of AIBILI and aims to evaluate the effectiveness of educational materials for healthcare professionals and the target general population, as additional measures of risk minimization for the drugs Vabysmo® (faricimab), Eylea® (aflibercept) and Lucentis® (ranibizumab).

More information: https://www.infarmed.pt/web/infarmed/infarmed/-/journal_content/56/15786/9521902

Presentations:

• Abnormal retinal fluid in eyes with diabetic center-involved macular edema

Prof. José Cunha-Vaz

 

• A Conversion Model for OCTA Vessel Density Metrics in Diabetic Eyes: Angiovue vs Cirrus Angioplex

Doutora Ana Rita Santos

 

• Statins and genetics in the risk of progression of age-related macular degeneration – The Coimbra Eye Study

Dra. Patrícia Barreto

 

• Combination of Ultra-widefield Colour Fundus Photography and Optical Coherence Tomography Angiography identify different subtypes of non-proliferative diabetic retinopathy

Dra. Ana Almeida

 

Posters:

• CLARUS (or Wide-Field Fundus Imaging) Improves ETDRS Grading with Classic 7-fields Fundus Photographs

Dra. Marta Lopes

 

Audio narrated free paper:

• Statin intake time and risk for progression of age-related macular degeneration – a comparison of two Cox regression models applied to the Coimbra Eye Study

Doutora Rita Coimbra

AIBILI will be presenting at EVOLVE – Digital Transformation Summit 2023 the EVICR.net Eye Platform. This summit will be organised by APDC on October 11, 2023, in Lisbon, Portugal. The EVICR.net Eye Platform is a long-term initiative to collect longitudinal anonymised clinical data and eye images from the network’s centers across Europe. The data platform will be available for analysis by all EVICR.net partners to develop a better understanding of the progression of eye diseases and new ways to improve patient care and prevent vision loss.
Boehringer Ingelheim is funding the EVICR.net Eye Platform and a pilot study that is collecting and will analyze data in patients with intermediate AMD or early atrophic AMD.
Learn more at: https://www.evicr.net/eyeplatform/

AIBILI was present at this ERA4Health workshop – Analysis of bottlenecks and challenges in designing and conducting investigator-initiated multinational clinical studies – through Dr. Cecília Martinho and Dr. Joana Tavares, which took place in Paris, France, on 15-16/09/2023. Challenges in designing and conducting investigator-initiated multinational clinical studies were discussed.

‘À Mesa com Saúde’ is a health literacy initiative organized by Faculty of Medicine of the Coimbra University and iCBR – Coimbra Institute for Clinical and Biomedical Research, in partnership with the Coimbra School of Tourism and the Coimbra University Hospital, which consists of organizing dinners commented by chefs, scientists and clinicians, which aim to address diseases and their prevention through diet. The dinner on May 5th has Vision Sciences as its theme and has the participation of Dr. Patricia Barreto from AIBILI.

AIBILI, as Coordinating Centre of EVICR.net, is organizing the EVICR.net 18th Members Meeting on October 19-20, 2023, in Milan, Italy.

AIBILI will be organising the EAsDEC congress 2023 on June 1-3, 2023 in Coimbra Portugal.

Do not miss the opportunity to joint a forum of ophthalmologists and diabetologists aimed at increasing the understanding of diabetic retinopathy, its development, diagnosis and treatment.

For more information and registration please visit: https://www.easdec.org/pages/default.asp?id=2

AIBILI has been recognised as an EATRIS Expert Centre covering areas as regulatory strategy and execution and health technology assessment.

EATRIS put out a call for an expression of interest from institutions to provide EATRIS decentralised expert services. Seven applied and were ratified by the EATRIS Boards. The Centres cover a wide range of areas, such as innovation management, regulatory strategy and execution, and health technology assessment.

AIBILI 2022 report is now available!

Please check it here.

Proud to have Patrícia Barreto from AIBILI AMD Research Group receiving the Plácido Prize by the Sociedade Portuguesa de Oftalmologia, during the 65th Portuguese Congress of Ophthalmology.

 

The work entitled “Genetics and the Mediterranean diet: What is the risk for Age-Related Macular Degeneration” was developed by Patrícia Barreto. The assessment of each individual’s genetic risk may be relevant to assess the benefit of personalized non-pharmacological strategies, namely modifiable risk factors for the prevention of Age-Related Macular Disease.

 

Co-workers: Patrícia Barreto, Cláudia Farinha, Rita Coimbra, Maria Luz Cachulo, Joana Barbosa de Melo, Carel Hoyng, Yara Lechanteur, José Cunha-Vaz and Rufino Silva.

To celebrate the 30 years of INFARMED and for the first time in Portugal the National Pharmacovigilance Day, INFARMED organises on 13/12/2022 a session in Lisbon.

AIBILI is one of the Regional Pharmacovigilance Units and its Coordinator, Dr. Lisete Lemos will have a talk dedicated to the challenges and opportunities for the Regional Units.

For more information please check here.

 

Nesta edição do boletim “FARMACOVIGILÂNCIA: Atualizações de segurança de medicamentos” informa-se acerca de novas recomendações no tratamento da síndrome hepatorrenal com medicamentos que contêm terlipressina, recomendações sobre medidas de minimização do risco de reações adversas graves para os medicamentos da classe de inibidores das JAK utilizados em doenças inflamatórias, bem como informação sobre a revisão do perfil de segurança do Topamax® (topiramato) no seguimento de um estudo que revelou risco aumentado de deficiências no neurodesenvolvimento em crianças com exposição pré-natal, e ainda um alerta sobre o uso de vacinas vivas em lactentes cujas mães receberam ustecinumab durante a gravidez. Destacam-se ainda atualizações de segurança sobre as vacinas e medicamentos aprovados para a COVID-19. Por último, é apresentada a atividade científica da Unidade de Farmacovigilância de Coimbra (UFC) e os resultados da sua atividade no terceiro trimestre de 2022.

Consulte: Farmacovigilância – Atualizações de segurança de medicamentos, Vol. 9, n.º 1

Diabetes is a health condition that can affect many parts of the body, including the eyes. Routine eye exams can help identify the early stages of eye problems and protect a person’s vision.